Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2024-04-24 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
中审亚太会计师事务所关于北京诺思兰德生物技术股份有限公司内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes a self-evaluation report on the effectiveness of internal controls for the fiscal year ending December 31, 2023. It is issued by an accounting firm (中审亚太审字) and contains detailed descriptions of the internal control environment, risk assessments, control activities, information and communication, and control supervision. The document focuses on the audit and verification of internal controls related to financial reporting and compliance with regulatory standards. It does not contain full financial statements or comprehensive annual or interim financial results, but rather an audit opinion on internal control effectiveness. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal control assessments, excluding full annual reports. The document length (9381 characters) and content confirm it is a full report, not just an announcement or certification letter, so it is not classified as RPA or RNS. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-24 Chinese
监事会关于部分限制性股票回购注销及注销部分股票期权的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board's verification opinion regarding the repurchase and cancellation of restricted stocks and stock options under the company's equity incentive plan. It references compliance with relevant laws and regulations, and confirms the cancellation and repurchase of shares and options. This is a report related to transactions in the company's own shares, specifically share repurchase and cancellation of stock options. The document length is short (1081 characters) but contains substantive content about share repurchase and cancellation, not just an announcement or certification. Therefore, it fits best under the category of Transaction in Own Shares (POS).
2024-04-24 Chinese
董事会关于独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence of the company's independent directors. It references regulatory rules about independent directors and confirms their independence status. The document is short (914 characters) and is a specific report on board/management information related to director independence. It is not an annual report, audit report, or any financial report. It is not an announcement of voting results or a proxy statement. Therefore, the best fitting category is Board/Management Information (MANG).
2024-04-24 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告 2023' which translates to 'Annual Report 2023'. It contains detailed sections typical of an annual report such as company overview, management discussion and analysis, financial data, risk factors, and corporate governance. The document includes comprehensive financial statements, management's discussion of business operations, and detailed notes on company activities throughout the year 2023. It also references the audit report by an accounting firm with an unqualified opinion, which is standard in annual reports. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-24 Chinese
利润分配管理制度
Governance Information Classification · 95% confidence The document is titled as a "Profit Distribution Management System" issued by Beijing Northland Biotechnology Co., Ltd. It details the company's policies and procedures for profit distribution, including dividend policies, decision-making processes, and compliance with relevant laws and regulations. The document is a formal announcement of the company's internal profit distribution management system, approved by the board and pending shareholder approval. It does not contain financial statements or actual financial results but rather outlines governance and procedural rules related to profit distribution. This type of document fits best under Governance Information (CGR), as it details internal rules and governance practices related to profit distribution policies.
2024-04-24 Chinese
独立董事述职报告(王英典）
Board/Management Information Classification · 95% confidence The document is titled '2023 年度独立董事述职报告（王英典）' which translates to '2023 Annual Independent Director's Work Report (Wang Yingdian)'. It is a detailed report by an independent director about their duties, attendance, committee participation, and opinions during the year 2023. The content focuses on the director's role, governance, and oversight activities rather than financial results or audit opinions. It is not an announcement of voting results, nor a proxy statement, nor a remuneration report. It is a governance-related report detailing the independent director's work and compliance with governance rules. Therefore, the document fits best under Board/Management Information (MANG) as it relates to board member duties and governance activities. The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement or certification. Hence, the classification is MANG with high confidence.
2024-04-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.